De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT)-Reference-Cited by-同舟云学术

De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT)

Published:2018-11-29 Issue:1 Volume:13 Page:
ISSN:1748-5908
Container-title:Implementation Science
language:en
Short-container-title:Implementation Sci

Author:

Skolarus Ted A.,Hawley Sarah T.,Wittmann Daniela A.,Forman Jane,Metreger Tabitha,Sparks Jordan B.,Zhu Kevin,Caram Megan E. V.,Hollenbeck Brent K.,Makarov Danil V.,Leppert John T.,Shelton Jeremy B.,Shahinian Vahakn,Srinivasaraghavan Sriram,Sales Anne E.

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Informatics,Health Policy,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13012-018-0833-7.pdf

Reference80 articles.

1. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006;98(12):839–45.

2. Gilbert SM, Kuo YF, Shahinian VB. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol. 2011;29(6):647–53.

3. Skolarus TA, Wolf AM, Erb NL, Brooks DD, Rivers BM, Underwood W 3rd, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014;64(4):225–49.